Jilin Aodong Pharmaceutical Group Co Ltd (000623) - Net Assets

Latest as of March 2026: CN¥31.71 Billion CNY ≈ $4.64 Billion USD

Based on the latest financial reports, Jilin Aodong Pharmaceutical Group Co Ltd (000623) has net assets worth CN¥31.71 Billion CNY (≈ $4.64 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥35.27 Billion ≈ $5.16 Billion USD) and total liabilities (CN¥3.55 Billion ≈ $519.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Jilin Aodong Pharmaceutical Group Co Ltd (000623) total assets for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥31.71 Billion
% of Total Assets 89.92%
Annual Growth Rate 20.03%
5-Year Change 23.36%
10-Year Change 63.65%
Growth Volatility 31.77

Jilin Aodong Pharmaceutical Group Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Jilin Aodong Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Jilin Aodong Pharmaceutical Group Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Jilin Aodong Pharmaceutical Group Co Ltd (1993–2025)

The table below shows the annual net assets of Jilin Aodong Pharmaceutical Group Co Ltd from 1993 to 2025. For live valuation and market cap data, see market cap of Jilin Aodong Pharmaceutical Group Co Ltd.

Year Net Assets Change
2025-12-31 CN¥30.89 Billion
≈ $4.52 Billion		 +5.48%
2024-12-31 CN¥29.28 Billion
≈ $4.28 Billion		 +6.48%
2023-12-31 CN¥27.50 Billion
≈ $4.02 Billion		 +4.41%
2022-12-31 CN¥26.34 Billion
≈ $3.85 Billion		 +5.19%
2021-12-31 CN¥25.04 Billion
≈ $3.66 Billion		 +6.42%
2020-12-31 CN¥23.53 Billion
≈ $3.44 Billion		 +4.83%
2019-12-31 CN¥22.44 Billion
≈ $3.28 Billion		 +5.65%
2018-12-31 CN¥21.24 Billion
≈ $3.11 Billion		 +3.56%
2017-12-31 CN¥20.51 Billion
≈ $3.00 Billion		 +8.69%
2016-12-31 CN¥18.87 Billion
≈ $2.76 Billion		 +7.34%
2015-12-31 CN¥17.58 Billion
≈ $2.57 Billion		 +38.90%
2014-12-31 CN¥12.66 Billion
≈ $1.85 Billion		 +14.04%
2013-12-31 CN¥11.10 Billion
≈ $1.62 Billion		 +13.81%
2012-12-31 CN¥9.75 Billion
≈ $1.43 Billion		 +7.24%
2011-12-31 CN¥9.09 Billion
≈ $1.33 Billion		 +25.52%
2010-12-31 CN¥7.25 Billion
≈ $1.06 Billion		 +10.45%
2009-12-31 CN¥6.56 Billion
≈ $959.99 Million		 +27.56%
2008-12-31 CN¥5.14 Billion
≈ $752.55 Million		 +5.09%
2007-12-31 CN¥4.89 Billion
≈ $716.08 Million		 +109.54%
2006-12-31 CN¥2.34 Billion
≈ $341.74 Million		 +38.10%
2005-12-31 CN¥1.69 Billion
≈ $247.45 Million		 +3.62%
2004-12-31 CN¥1.63 Billion
≈ $238.80 Million		 +20.80%
2003-12-31 CN¥1.35 Billion
≈ $197.69 Million		 +6.24%
2002-12-31 CN¥1.27 Billion
≈ $186.07 Million		 +7.82%
2001-12-31 CN¥1.18 Billion
≈ $172.57 Million		 +7.13%
2000-12-31 CN¥1.10 Billion
≈ $161.09 Million		 +57.73%
1999-12-31 CN¥697.92 Million
≈ $102.13 Million		 +13.41%
1998-12-31 CN¥615.37 Million
≈ $90.05 Million		 +85.08%
1997-12-31 CN¥332.48 Million
≈ $48.65 Million		 +36.79%
1996-12-31 CN¥243.07 Million
≈ $35.57 Million		 +135.94%
1995-12-31 CN¥103.02 Million
≈ $15.07 Million		 +29.05%
1994-12-31 CN¥79.83 Million
≈ $11.68 Million		 -10.99%
1993-12-31 CN¥89.69 Million
≈ $13.12 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Jilin Aodong Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2134385536310.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥21.34 Billion 69.60%
Other Components CN¥9.32 Billion 30.40%
Total Equity CN¥30.67 Billion 100.00%

Jilin Aodong Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Jilin Aodong Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
CSSC Offshore & Marine Engineering Group Co Ltd
SHG:600685
 $3.09 Billion
Asker Healthcare
ST:ASKER
 $3.10 Billion
Avicopter PLC
SHG:600038
 $3.10 Billion
Airoha Technology Corp
TW:6526
 $3.10 Billion
Concentra Group Holdings Parent, Inc.
NYSE:CON
 $3.09 Billion
Shyam Metalics and Energy Limited
NSE:SHYAMMETL
 $3.09 Billion
TOTVS S.A
SA:TOTS3
 $3.09 Billion
Westgold Resources Ltd
AU:WGX
 $3.09 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jilin Aodong Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 29,027,588,245 to 30,666,757,532, a change of 1,639,169,287 (5.6%).
  • Net income of 2,395,240,135 contributed positively to equity growth.
  • Dividend payments of 649,028,999 reduced retained earnings.
  • Other comprehensive income decreased equity by 7,300,396,191.
  • Other factors increased equity by 7,193,354,342.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥2.40 Billion +7.81%
Dividends Paid CN¥649.03 Million -2.12%
Other Comprehensive Income CN¥-7.30 Billion -23.81%
Other Changes CN¥7.19 Billion +23.46%
Total Change CN¥- 5.65%

Book Value vs Market Value Analysis

This analysis compares Jilin Aodong Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.69x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 199.71x to 0.69x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.09 CN¥17.67 x
1996-12-31 CN¥0.21 CN¥17.67 x
1997-12-31 CN¥0.29 CN¥17.67 x
1998-12-31 CN¥0.49 CN¥17.67 x
1999-12-31 CN¥0.57 CN¥17.67 x
2000-12-31 CN¥0.92 CN¥17.67 x
2001-12-31 CN¥0.89 CN¥17.67 x
2002-12-31 CN¥0.95 CN¥17.67 x
2003-12-31 CN¥1.02 CN¥17.67 x
2004-12-31 CN¥1.12 CN¥17.67 x
2005-12-31 CN¥1.19 CN¥17.67 x
2006-12-31 CN¥1.75 CN¥17.67 x
2007-12-31 CN¥3.96 CN¥17.67 x
2008-12-31 CN¥4.16 CN¥17.67 x
2009-12-31 CN¥5.37 CN¥17.67 x
2010-12-31 CN¥6.18 CN¥17.67 x
2011-12-31 CN¥7.77 CN¥17.67 x
2012-12-31 CN¥8.29 CN¥17.67 x
2013-12-31 CN¥9.45 CN¥17.67 x
2014-12-31 CN¥10.84 CN¥17.67 x
2015-12-31 CN¥14.95 CN¥17.67 x
2016-12-31 CN¥16.22 CN¥17.67 x
2017-12-31 CN¥17.44 CN¥17.67 x
2018-12-31 CN¥18.09 CN¥17.67 x
2019-12-31 CN¥17.39 CN¥17.67 x
2020-12-31 CN¥18.30 CN¥17.67 x
2021-12-31 CN¥19.75 CN¥17.67 x
2022-12-31 CN¥20.01 CN¥17.67 x
2023-12-31 CN¥22.87 CN¥17.67 x
2024-12-31 CN¥24.66 CN¥17.67 x
2025-12-31 CN¥25.64 CN¥17.67 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jilin Aodong Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 7.81%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 102.57%
  • • Asset Turnover: 0.07x
  • • Equity Multiplier: 1.12x
  • Recent ROE (7.81%) is below the historical average (12.83%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 25.18% 14.98% 0.70x 2.40x CN¥15.63 Million
1996 16.30% 16.33% 0.58x 1.73x CN¥15.32 Million
1997 26.89% 27.06% 0.59x 1.68x CN¥56.17 Million
1998 14.37% 22.16% 0.44x 1.46x CN¥24.81 Million
1999 15.02% 26.02% 0.33x 1.74x CN¥33.54 Million
2000 7.59% 25.80% 0.22x 1.34x CN¥-25.74 Million
2001 3.15% 7.28% 0.26x 1.64x CN¥-70.64 Million
2002 6.82% 13.17% 0.30x 1.70x CN¥-35.21 Million
2003 8.37% 14.71% 0.35x 1.65x CN¥-19.23 Million
2004 8.96% 14.24% 0.33x 1.93x CN¥-13.61 Million
2005 8.00% 14.40% 0.30x 1.82x CN¥-27.66 Million
2006 23.90% 63.25% 0.23x 1.61x CN¥283.36 Million
2007 43.23% 235.73% 0.15x 1.22x CN¥1.53 Billion
2008 17.79% 92.86% 0.16x 1.19x CN¥377.18 Million
2009 21.84% 133.25% 0.14x 1.14x CN¥740.67 Million
2010 17.24% 111.17% 0.14x 1.10x CN¥519.93 Million
2011 21.98% 173.07% 0.11x 1.12x CN¥1.08 Billion
2012 6.68% 44.72% 0.13x 1.13x CN¥-320.81 Million
2013 9.61% 54.11% 0.16x 1.10x CN¥-43.21 Million
2014 11.21% 62.97% 0.16x 1.09x CN¥152.57 Million
2015 14.92% 111.09% 0.12x 1.14x CN¥855.71 Million
2016 8.94% 60.89% 0.13x 1.09x CN¥-197.42 Million
2017 9.19% 62.60% 0.14x 1.08x CN¥-164.20 Million
2018 4.45% 28.13% 0.13x 1.17x CN¥-1.17 Billion
2019 6.31% 45.45% 0.12x 1.16x CN¥-821.31 Million
2020 7.32% 75.89% 0.08x 1.17x CN¥-626.43 Million
2021 7.16% 77.29% 0.08x 1.17x CN¥-705.45 Million
2022 6.84% 62.09% 0.09x 1.20x CN¥-822.60 Million
2023 5.36% 42.33% 0.11x 1.19x CN¥-1.26 Billion
2024 5.34% 59.43% 0.08x 1.14x CN¥-1.35 Billion
2025 7.81% 102.57% 0.07x 1.12x CN¥-671.44 Million

Industry Comparison

This section compares Jilin Aodong Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,015,895,203
  • Average return on equity (ROE) among peers: 6.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jilin Aodong Pharmaceutical Group Co Ltd (000623) CN¥31.71 Billion 25.18% 0.11x $3.09 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $7.85 Billion 2.63% 4.24x $589.07 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $765.24 Million 1.30% 0.72x $353.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $3.48 Billion 24.64% 0.22x $4.79 Billion
Livzon Pharmaceutical Group Inc (000513) $972.07 Million 4.20% 0.48x $2.58 Billion
Wedge Industrial Co Ltd (000534) $600.19 Million 1.64% 0.34x $1.86 Billion
Yunnan Baiyao Group Co Ltd (000538) $279.81 Million 10.28% 0.26x $13.32 Billion
Hainan Haiyao Co Ltd (000566) $1.49 Billion 5.19% 0.85x $915.05 Million
Tus Pharmaceutical Group Co Ltd (000590) $644.88 Million 3.52% 0.38x $270.18 Million
Northeast Pharmaceutical Group Co Ltd (000597) $2.07 Billion 2.59% 1.71x $939.73 Million

About Jilin Aodong Pharmaceutical Group Co Ltd

SHE:000623 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.09 Billion
CN¥21.13 Billion CNY
Market Cap Rank
#4744 Global
#766 in China
Share Price
CN¥17.67
Change (1 day)
-3.50%
52-Week Range
CN¥16.52 - CN¥21.82
All Time High
CN¥24.39
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Jilin Aodong Pharmaceutical Group Co., Ltd. manufactures and sells pharmaceutical products in China. It provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It is also involved in the highway construction … Read more